Member Info for mazik

Thank U Aim4u great research material :-)

Could be an RNS updating the resources we have and update of Marietta drilling or a takeover while its cheap

MM cannot cap this share for too long, if investors take position this measly SP will be history

Beaufort Target of 10p is an initial valuation,, further update on NXP001 and licensing deals will revalue in multiples of Beaufort Target IMO...its fully funded and moving at the right direction.

Who are these sellers? short termers or spreadex off loading

Aim you are right, the added benefit it has main listing and will draw instituition..IMO

I have done my research and have put it up last night, its a multibag in waiting. Fully funded , with excellent bod at the helm...

There is persistent buying now once investors have digested a very positive RNS...MM do not know how to play this, they are just into shake rattle and roll...

Hmmm I have loaded 175k shares on three transaction ...well they gave mecheap i did oblige them :-)

250 block buyer is at it again, though the impatient short termers sold on back of a fantastic RNS..IMO :-)

Great news the MM cannot keep the sp capped, and neither their tree shake will work after such a fantastic news IMO

Immediate out licensing � Strong pre-clinical data coupled with proof of effective oral delivery would create a high-value out-licensing opportunity � This is demonstrated by several recently completed deals at a similar stage of development: - Shire acquired Fibrotech (May 2014): $75m upfront + up to $600m - BMS acquired Galecto (Nov 2014): Total value potential $444m Build greater asset value � Informed by the pre-clinical programme, proof-of-concept in patients would generate substantially greater value - BMS acquired Promedior (Aug 2015): $150m upfront + up to $1.25bn � Possibility to self-fund from NXP001 out-licensing revenue � Potential to decrease clinical development costs and time - Fast-track status or orphan designation available in fibrosis - Advances in fibrosis biomarkers and non-invasive imaging techniques allowing more accurate, faster clinical trials We can see NFX sitting ay �2 per share and in the ftse250..... I am elated and thanking MM to give us opportunity to top up :-)

Buyer of 250k blocks had to via Auction...something is cooking :-)

With 4 auction in a day, something is definately on..mm will bring this back to 4p the staging point before news. I am very confident, fully funded, something big is coming as our partners like it "BIG"... Big Health, Big Dream, Big Industry, Big Value�, and it was hosted by Shanghai Newsummit Biopharma Chief Human Officer of, Ms. Lei Cao.. We have access to Big market in China via Newsummit" ...well news of NX001 is released our will cross , and save our MMs to stop the rinse and repeat game.

Well I am full up, MM can auction and play their games, when spreadex are out we will see double digits on news IMO

Games to keep it down, topping up since last 8 weeks , got 900 k...I feel i will look at it end of this year or when it reahes double digit figures...GLA

A hidden gem, hopefully news is due soon

www.**********************/shp/research.php?vid=487www.**********************/shp/research.php?vid=487

Oncology Supportive Care, A $20bn market place, But Also A Double-Edged Lifestyle Sword Looking at Oncology and Oncology Supportive Care; cancer rates in humans are soaring globally due to changing demographics and lifestyles, but cancer treatments are also increasingly successful in extending human life. That said, the side effects of cancer treatment can force treatment delays and dose reductions in up to 75% of cancer patients and some 35% of treatments end up being permanently ceased due to the vicious treatment side effects which patients suffer. Under Nuformix�s NXP001 programme , the company has developed a drug cocrystal which is bioequivalent to a patented marketed treatment in OSC. Importantly, NFX�s cocrystal technology approach also provides intellectual property (IP) protection for this new drug under new �substance of matter� patent laws which circumvent the existing product�s IP protection. Reduced product complexity also means the Nuformix product is likely to be signaficantly cheaper

Topped up again , NFX fully funded, main market I will not be surprised with a re rate as now we are buying at below flotation price IMO...�1 are u joking:-)